The efficacy of 250 mg/day flutamide in the treatment of patients with hirsutism.
OBJECTIVE
To investigate the effects of low dose flutamide (250 mg/d) on hirsutism score and hormone levels in women with hirsutism.


METHODS
Nonrandomized, prospective clinical trial.


METHODS
Forty-one patients with moderate-severe hirsutism were included in the study.


METHODS
Hirsute patients received 250 mg/d flutamide for a period of 6 months.


METHODS
Hirsutism score, FSH, LH, E2, total T, free T, androstenedione, DHEAS, PRL, 17-hydroxyprogesterone, and sex hormone-binding globulin levels were detected in all the patients before treatment and every 3 months during treatment.


RESULTS
Treatment with the antiandrogen flutamide resulted in a particularly rapid and marked decrease in the hirsutism score, which decreased from 17.48 +/- 5.35 to 5.07 +/- 2.89 after 6 months. No significant changes in the levels of hormone and no serious side effects were observed in the study.


CONCLUSIONS
The low-dose flutamide, 250 mg/d, is a cost-effective drug in the treatment of hirsutism. Low-dose flutamide may be used in place of high-dose flutamide, 500 to 750 mg/d.
Müderris
I I
II
Erciyes University, Faculty of Medicine, Kayseri, Turkey.
Bayram
F
F
Sahin
Y
Y
Keleştimur
F
F
Tutuş
A
A
Ayata
D
D
D000293:Adolescent; D000328:Adult; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000735:Androstenedione / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004967:Estrogens / Q000097:blood; D005260:Female; D005485:Flutamide / Q000627:therapeutic use*; D005640:Follicle Stimulating Hormone / Q000097:blood; D006628:Hirsutism / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D011374:Progesterone / Q000097:blood; D011446:Prospective Studies; D013739:Testosterone / Q000097:blood
D000726:Androgen Antagonists; D004967:Estrogens; D013739:Testosterone; D000735:Androstenedione; D011374:Progesterone; D005485:Flutamide; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone